Table 1.

Patients in high-risk subgroup categories (CE population)

CAP			HAP (excluding VAP)
Baseline risk factor	Ceftobiprole	Ceftriaxone ± linezolid	Baseline risk factor	Ceftobiprole	Ceftazidime plus linezolid
Any risk factor	193	205	Any risk factor	169	138
PORT ≥ III	126	117	APACHE score ≥ 15	67	59
PORT ≥ IV	51	58	>10 comorbidities	63	61
Sepsis	123	135	Mechanical ventilationa	38	37
Bacteraemiab	7	14	Bacteraemiab	15	11
Age ≥ 75 years	39	50	Age ≥ 75 years	59	54
COPD	51	59	COPD	55	39
ICU	25	26	ICU	73	59

^aMechanical ventilation at baseline or at any point during the study

^bFurther analyses were not conducted in the bacteraemia group as the number of patients in both treatment arms was below 20

APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, COPD chronic obstructive pulmonary disease, HAP hospital-acquired pneumonia, ICU intensive care unit, PORT Patient Outcome Research Team, VAP ventilator-associated pneumonia